ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Altimmune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.23+0.03 (+1.36%)
Close on Oct 19, 2026
- Market cap
- $413.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.60 (−41.78%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Altimmune, Inc. grew revenue 105.0% to $41.00K over fiscal 2025. Free cash flow was -$76.56M.
Revenue
$41.00K
+105.0% vs. a year earlier
Operating income
-$100.23M
TTM Q2 2026
Free cash flow
-$76.56M
TTM Q2 2026
EPS, diluted
-$0.77
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $413.54M
- P/E ratio
- –
- Price to sales
- 10086.33
- Price to book
- 0.87
- Dividend yield
- –
- Free cash flow yield
- -18.51%
Fundamentals
- Revenue
- $41.00K
- Net income
- -$91.76M
- EPS, diluted
- -$0.77
- Free cash flow
- -$76.56M
- Book value per share
- $2.56
- Diluted shares
- 185M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$100.23M
Net income
-$91.76M
EPS, diluted
-$0.77
Free cash flow
-$76.56M
Reported periodTrailing twelve months